Tag - eisai-co

 
 

EISAI CO

Japan Times
BUSINESS / Companies
Jul 11, 2023
Eisai appoints CEO’s son to lead global Alzheimer drug program
Eisai's former global Alzheimer drug program officer, who led the push for U.S. approval of breakthrough medicine Leqembi, will retire at the end of the month.
Japan Times
WORLD / Science & Health
Jul 7, 2023
Eisai Alzheimer's drug gets full U.S. approval, widening access to the therapy
The broader clearance from the Food and Drug Administration marks a milestone for treatment of the dementia that afflicts some 6 million Americans.
Japan Times
JAPAN / Science & Health / FOCUS
Jul 4, 2023
Expectations grow for Alzheimer's drug in Japan, but hurdles remain
Lecanemab could be approved in the country as early as fall, but more specialist doctors and a patient screening system would be needed for widespread use.
Japan Times
WORLD / Science & Health
Jun 19, 2023
New Eisai and Biogen Alzheimer drug faces hurdles in Europe
Some doctors said its effect on the disease may not be clinically meaningful enough when weighed against the risk of brain swelling, its likely high price.
Japan Times
JAPAN
Jan 30, 2023
Priority review status given to Alzheimer's drug developed by Eisai and Biogen
The companies said priority review in Japan is granted to new medicines recognized as having high medical utility for serious diseases.
Japan Times
BUSINESS
Jan 16, 2023
Eisai and Biogen apply for approval of Alzheimer's drug in Japan
The two companies hope to gain approval by the end of the year following the U.S. Food and Drug Administration's decision earlier in the month to grant it fast-track approval.
Japan Times
BUSINESS / Markets
Jan 10, 2023
Eisai shares jump after FDA approves Alzheimer’s drug lecanemab
The drug, to be sold under the brand name Leqembi, was approved by the Food and Drug Administration under an accelerated pathway.
Japan Times
WORLD / Science & Health
Jan 7, 2023
Alzheimer’s drug made jointly by Japan's Eisai wins accelerated U.S. approval
The U.S. has called the drug 'an important advancement in the ongoing fight' against the debilitating disease. But its $26,000 price tag could put it out of reach for many.
Japan Times
JAPAN / Science & Health
Dec 22, 2022
Japan approves blood test to detect Alzheimer’s
Japan has approved one of the world’s first blood test kits to detect signs of Alzheimer’s disease, paving way for a simpler and speedier diagnosis of the ailment for which a therapy is on the horizon.
Japan Times
BUSINESS
Nov 30, 2022
Eisai Alzheimer’s drug sparks debate over benefits as risks like brain bleeding emerge
The key issue is whether the modest slowing of the disease is meaningful to individual patients and their families, especially in light of the potential side effects.
Japan Times
BUSINESS / Markets
Nov 29, 2022
Eisai and Biogen plunge after report of second death in Alzheimer’s trial
The case involved a 65-year-old woman who died of a massive brain hemorrhage after suffering a stroke and a type of brain swelling and bleeding in an Eisai trial, a report said.
Japan Times
COMMENTARY / World
Oct 4, 2022
New Alzheimer's drug from Biogen and Eisai is just the beginning
A successful late-stage trial of lecanemab gives researchers promising new avenues for tackling this hard-to-beat disease.
Japan Times
WORLD / Science & Health / ANALYSIS
Sep 30, 2022
Eisai drug's trial success raises hope for Alzheimer's prevention
Scientists have already begun to debate whether the benefit of the drug is robust enough, but to many researchers, the findings suggest that preventing decline altogether is possible.
Japan Times
JAPAN / Science & Health
Sep 28, 2022
Alzheimer’s progression slowed by drug in major trial
The drug slowed cognitive decline in people with early Alzheimer's by 27% over 18 months when compared with a placebo using a common rating scale.
Japan Times
BUSINESS / Companies
Jul 6, 2022
Eisai says Alzheimer’s drug will get priority review in U.S.
Under the accelerated approval pathway, drugs can be approved based on their ability to remove amyloid, a hallmark of the disease, from the brain.
Japan Times
BUSINESS
Apr 9, 2022
Japan's Eisai still seeking accelerated U.S. review of Alzheimer's drug
The firm said it plans to seek a quick approval even after the Medicare health plan decided to limit coverage of medicines approved in that manner.
Japan Times
WORLD / Science & Health
Jan 12, 2022
Biogen stung as U.S. limits coverage of Alzheimer’s therapy
Private insurers in the U.S. have mostly declined to cover Aduhelm, saying they need more proof of its efficacy and that benefits outweigh risks like brain swelling.
Japan Times
BUSINESS / Companies
Jul 13, 2021
Eisai pushes second Alzheimer's drug despite call to probe U.S. approval of first
The U.S. Food and Drug Administration's June approval of Aduhelm caused resignations among a panel of independent experts who said the therapy was ineffective.
Japan Times
WORLD / Science & Health / ANALYSIS
Jun 11, 2021
U.S. FDA faces mounting criticism over Alzheimer's drug approval
The drug was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of the disease.
Japan Times
BUSINESS
Jun 9, 2021
Eisai sees potential of new Alzheimer's drug but costs remain concern
The approval by the U.S. Food and Drug Administration of the drug Aduhelm raised hopes, but patients can expect to be charged $56,000 a year.

Longform

High-end tourism is becoming more about the kinds of experiences that Japan's lesser-known places can provide.
Can Japan lure the jet-set class off the beaten path?